



News Release

Suven Life secures One (1) Product Patent each in Australia & Hong Kong, two (2) product patents from Japan

HYDERABAD, INDIA (JAN 20, 2015) – Suven Life Sciences Ltd (Suven) announces today that its drug discovery portfolio which has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators resulted in the grant of **one (1) product patent from Australia (2010337837), two product patents from Japan (5536227,5588018) and one (1) product patent from Hong kong (1174913)** corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030

The granted claims of the patents include the class of **selective alpha-4-beta-2 compounds discovered by Suven** and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of **nineteen (19) granted patents from Australia, fourteen (14) granted patents from Japan and fifteen (15) granted patents from Hong Kong**. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

““We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **The Company has eleven (11) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity in addition to Phase 2 ready developmental candidate SUVN-502 for and Phase1 candidate SUVN-G3031 for Alzheimer’s disease and Schizophrenia.**

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;